Cocrystal pharma receives fda ind clearance for challenge study of oral broad-spectrum protease inhibitor cdi-988, a potential first antiviral for norovirus prevention and treatment

There are currently no approved vaccines or treatments for norovirus infection cocrystal's cdi-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections phase 1b study is expected to start by year-end 2025 bothell, wash., sept. 08, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces that the company received a study may proceed letter from the u.s. food and drug administration (fda) to conduct a phase 1b challenge study evaluating cdi-988 for the prevention and treatment of norovirus infections.
COCP Ratings Summary
COCP Quant Ranking